BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin (BBP-870/ORGN001) in Israel.
Fosdenopterin is a cPMP replacement therapy designed to treat patients with MoCD Type A. Origin recently initiated the rolling submission of a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for fosdenopterin. Subsequent to FDA approval, Medison will be responsible for seeking the requisite regulatory approval and, once approved, commercializing fosdenopterin in Israel. Origin will receive an upfront cash payment and will receive milestone payments upon the achievement of certain milestone events and ongoing royalties on net sales of fosdenopterin in Israel.
"Our partnership with Medison marks an important step in Origin’s global commercial strategy and strengthens our ability to make fosdenopterin available to infants and children suffering from MoCD Type A,” said Matt Outten, Chief Commercial Officer at BridgeBio. “Medison has a strong commercial organization in Israel with a proven track record of successfully marketing orphan disease products. Its commercial infrastructure is uniquely suited to support patients suffering from rare diseases like MoCD Type A. We look forward to collaborating with Medison to enhance our efforts to help patients by targeting MoCD Type A at its source.”
“Our promise is to assure that every patient under our responsibility has access to the best available treatments,” said Meir Jakobsohn, the founder and CEO of Medison Pharma. “The partnership with Origin Biosciences echoes our shared internal values of scientific excellence."
Fosdenopterin has received Orphan Drug Designation in the US and Europe, and Rare Pediatric Disease Designation and Breakthrough Therapy Designation in the United States. Since the NDA for fosdenopterin is seeking approval of treatment for patients with a serious and life-threatening disease with no other treatment options (MoCD Type A), it is also eligible for Priority Review Designation, which, if granted, may further expedite the NDA review time for the potential approval of this new medicine in the United States.
For the complete Press Release: https://www.globenewswire.com